Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03378310 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03378310 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 16 participants.
The verdict
NCT03378310, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, randomized study in healthy participants to evaluate the absorption of a BMS-986205 tablet into the bloodstream compared to a reference tablet. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single, oral dose of BMS-986205 twice over 22 days. Participants must remain at the clinical facility for the duration of the study.
Interventions
- DRUG BMS-986205 reference tablet
- DRUG BMS-986205 tablet with free base
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-12-21 |
| Est. Completion | 2018-02-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03378310
The ClinicalTrials.gov registry entry for NCT03378310 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986205 reference tablet is the first listed.
NCT03378310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03378310 about?
NCT03378310 is a clinical study titled "A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet". This is a Phase 1, open-label, randomized study in healthy participants to evaluate the absorption of a BMS-986205 tablet into the bloodstream compared to a reference tablet. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single, oral dose of BMS-986...
What is the current status of trial NCT03378310?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2017-12-21. Estimated completion is 2018-02-22.
What interventions are being tested in trial NCT03378310?
The interventions under investigation include: BMS-986205 reference tablet (DRUG), BMS-986205 tablet with free base (DRUG).
Who is sponsoring clinical trial NCT03378310?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.